Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:PBYINASDAQ:RNTXNASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.16+9.6%$1.58$0.91▼$6.05$164.92M2.12.57 million shs2.81 million shsPBYIPuma Biotechnology$3.45+3.0%$3.19$2.23▼$4.13$171.23M1.29443,734 shs228,779 shsRNTXRein Therapeutics$1.82-3.2%$1.86$1.35▼$4.40$40.32M1.350,293 shs10,686 shsSLSSELLAS Life Sciences Group$1.61-3.0%$1.54$0.77▼$2.12$160.64M2.251.58 million shs1.78 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+9.64%+11.92%+43.05%+64.26%-57.31%PBYIPuma Biotechnology+2.99%-4.17%+1.77%+3.29%+10.93%RNTXRein Therapeutics-3.19%-8.08%-17.65%-2.67%+181,999,900.00%SLSSELLAS Life Sciences Group-3.01%+2.55%-1.23%+49.07%+7.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.236 of 5 stars3.12.00.04.22.82.51.3PBYIPuma Biotechnology4.0036 of 5 stars3.52.00.00.02.43.33.1RNTXRein TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group0.5143 of 5 stars0.01.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.29Hold$5.36148.32% UpsidePBYIPuma Biotechnology 3.00Buy$7.00102.90% UpsideRNTXRein Therapeutics 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RNTX, PBYI, SLS, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$35.84M5.05N/AN/A$4.27 per share0.51PBYIPuma Biotechnology$232.71M0.74$0.82 per share4.19$1.12 per share3.08RNTXRein TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ASLSSELLAS Life Sciences Group$1M160.64N/AN/A($0.25) per share-6.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)PBYIPuma Biotechnology$21.59M$0.777.199.08N/A9.56%41.60%10.71%7/30/2025 (Estimated)RNTXRein Therapeutics-$15.73M-$2.86N/AN/AN/AN/A-74.08%-27.93%N/ASLSSELLAS Life Sciences Group-$37.34M-$0.38N/AN/AN/AN/A-629.46%-178.65%8/12/2025 (Estimated)Latest RNTX, PBYI, SLS, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RNTXRein Therapeutics-$0.21-$0.25-$0.04-$0.25N/AN/A5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million4/7/2025Q4 2024RNTXRein TherapeuticsN/A-$0.26N/A-$1.89N/AN/A3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.753.75PBYIPuma Biotechnology0.461.421.40RNTXRein TherapeuticsN/A3.303.30SLSSELLAS Life Sciences GroupN/A2.262.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%PBYIPuma Biotechnology61.29%RNTXRein Therapeutics90.89%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine2.10%PBYIPuma Biotechnology23.30%RNTXRein Therapeutics5.10%SLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million80.98 millionOptionablePBYIPuma Biotechnology20049.63 million37.45 millionOptionableRNTXRein Therapeutics922.15 million20.56 millionN/ASLSSELLAS Life Sciences Group1099.78 million69.54 millionNot OptionableRNTX, PBYI, SLS, and EDIT HeadlinesRecent News About These CompaniesSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short InterestJune 16 at 4:45 PM | marketbeat.comNostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 14 at 8:41 AM | insidertrades.comNostrand Robert L. Van Acquires 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 13, 2025 | marketbeat.comSELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology ExpertsJune 5, 2025 | globenewswire.comSELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025June 4, 2025 | nasdaq.comInsider Buying: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Purchases 20,000 Shares of StockJune 3, 2025 | marketbeat.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 SharesJune 3, 2025 | insidertrades.comSELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual MeetingJune 2, 2025 | globenewswire.com594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Bought by Brooklyn FI LLCMay 28, 2025 | marketbeat.comSELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common StockMay 16, 2025 | fxempire.comSellas doses first paediatric subject with AML in Phase II trial of SLS009May 16, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | finanznachrichten.deSELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | globenewswire.comSELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025April 28, 2025 | quiverquant.comSELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR ConferenceApril 28, 2025 | globenewswire.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%April 26, 2025 | aaii.comSELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual MeetingApril 23, 2025 | quiverquant.comSELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comSellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trialApril 9, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNTX, PBYI, SLS, and EDIT Company DescriptionsEditas Medicine NASDAQ:EDIT$2.16 +0.19 (+9.64%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$2.19 +0.03 (+1.39%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Puma Biotechnology NASDAQ:PBYI$3.45 +0.10 (+2.99%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$3.44 -0.01 (-0.14%) As of 06/16/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Rein Therapeutics NASDAQ:RNTX$1.82 -0.06 (-3.19%) As of 06/16/2025 04:00 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.SELLAS Life Sciences Group NASDAQ:SLS$1.61 -0.05 (-3.01%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$1.64 +0.03 (+1.86%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
